文献速递肾移植肾血管病与高血压

Fulacimstat在肾脏同种异体移植物中降低血管紧张素II:一项横断面探索性研究

Fulacimstat Reduces Angiotensin II in Kidney Allografts in a Cross-Sectional Exploratory Study.
PubMed 文献 · Kidney Int Rep · 2025-12-24

该横断面探索性单中心研究分析了55例肾移植受者和13例健康供肾的活检组织,采用质谱法和特异性酶抑制剂评估ACE与糜蛋白酶对肾内血管紧张素II生成的贡献。结果显示,移植超过2年的老化移植物中血管紧张素II生成从ACE依赖转向糜蛋白酶依赖,且无论是否使用RAS阻断,fulacimstat(BAY 1142524)均能高效抑制内源性糜蛋白酶依赖的血管紧张素II生成。

要点

  • 老化(>2年)肾移植移植物中血管紧张素II生成由ACE转向糜蛋白酶依赖
  • Fulacimstat可高效抑制人肾移植活检组织中糜蛋白酶依赖的血管紧张素II生成
  • 该效应不受治疗性RAS阻断影响,提示潜在治疗价值

核心结论

  • 糜蛋白酶是老化移植肾(>2年)中血管紧张素II生成的关键酶。
  • Fulacimstat(BAY 1142524)可抑制人肾移植移植物中血管紧张素II的生成,提示潜在治疗效应。

研究设计与样本

  • 横断面、探索性、单中心研究,分析55例肾移植受者和13例健康供肾的活检样本,部分使用治疗性RAS阻断。
  • 采用基于质谱的方法和特异性酶抑制剂进行代谢测定,评估ACE和糜蛋白酶的酶活性及其对肾内血管紧张素II生成的贡献。

主要发现

  • 与健康肾脏相比,老化(>2年)肾移植移植物中观察到血管紧张素II生成从ACE依赖向糜蛋白酶依赖的明显转变。
  • 无论是否使用RAS阻断,fulacimstat(BAY 1142524)均能高效抑制人肾移植活检组织中内源性糜蛋白酶依赖的血管紧张素II生成。

临床怎么用

  • 在肾移植受者中,尤其移植超过2年的老化移植物,糜蛋白酶依赖的血管紧张素II生成可能成为干预靶点。
  • Fulacimstat等糜蛋白酶抑制剂可能提供独立于RAS阻断的血管紧张素II抑制途径,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The nephroprotective effects of renin-angiotensin system (RAS) blockade after kidney transplantation (KTx) remain ambiguous. It has been shown that chymase and not angiotensin (Ang)-converting enzyme (ACE) is the most efficient Ang II-forming enzyme. Here, we investigated the efficacy of the novel and highly selective chymase inhibitor fulacimstat (BAY 1142524) on Ang II formation in human allograft biopsy tissue. METHODS: In this cross-sectional, exploratory single-center study we analyzed biopsy samples of KTx recipients (n = 55) and healthy kidney donors (n = 13) with and without therapeutic RAS blockade. Using a mass spectrometry-based approach and using specific enzyme inhibitors, we performed metabolic assays to study enzyme activities of ACE and chymase and their specific contribution to intrarenal Ang II formation. RESULTS: In contrast to healthy kidneys, a distinct shift from ACE toward chymase-dependent Ang II formation was observed in aged (> 2 years) kidney allografts. Irrespective of RAS blockade, we demonstrated high efficacy of fulacimstat (BAY 1142524) to inhibit endogenous chymase-dependent Ang II formation in biopsy tissues of human kidney allografts. CONCLUSION: Chymase is the key enzyme for Ang II production in aged graft vintage (> 2 years). Selective inhibition of tissue-specific chymase with fulacimstat (BAY 1142524) inhibits Ang II formation in human kidney allografts, indicating potential therapeutic effects.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kovarik JJ, Shoumariyeh T, Domenig O, et al. Fulacimstat Reduces Angiotensin II in Kidney Allografts in a Cross-Sectional Exploratory Study. Kidney Int Rep. 2025. PMID: 41624455. doi:10.1016/j.ekir.2025.103745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。